Overview

Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the effect of a single dose of two experimental levodopa/carbidopa/entacapone (L/C/E) treatment regimens versus standard L/C/E treatment regimen in Parkinson's disease (PD) patients with end-of-dose motor fluctuations in terms of duration of motor response after the first morning dose of levodopa. The secondary objective is to evaluate the safety of the L/C/E treatment regimens in patients with PD.
Phase:
Phase 2
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Carbidopa
Entacapone
Levodopa